Eli Lilly's Zepbound rises while Novo Nordisk's Ozempic levels off

Eli Lilly's Zepbound and Mounjaro beat Wall Street expectations while Novo Nordisk's Ozempic and Wegovy disappointed.

8/8/24 11:47AM

Eli Lilly may eventually catch up to Ozempic maker Novo Nordisk when it comes to selling the weight loss drugs that have boomed in popularity in recent years.

Eli Lilly reported on Thursday that sales for Zepbound, which it has only sold for less than a year, reached $1.2 billion, crushing Wall Street estimated. Mounjaro, a similar drug, reached $3.1 billion in sales, making the biggest money-maker on Eli Lilly's portfolio.

As of this quarter three of the four most lucrative drugs Eli Lilly sells are diabetes medications also used for weight loss. (The other is Verzenio, which treats breast cancer.)

Novo Nordisk on Wednesday reported a disappointing quarter for the first time since the boom in obesity medications. Sales for its weight loss drugs — Ozempic and Wegovy — missed expectations and appear to be leveling off.

Demand for weight loss drugs has led both companies to up production to avoid shortages. Eli Lilly and Novo Nordisk have each spent billions to increase production of their obesity drugs.

Earlier this year there were shortages of Ozempic, Novo Nordisk's best-selling drug that kicked off the weight loss drug craze. Those shortages have cleared up but it appears to have limited its growth this year.

Shortages remain for Wegovy, according to a database from the Food and Drug Administration. As of this month none of Eli Lilly's weight loss drugs are facing a shortage.

While Eli Lilly's weight loss drugs had a better quarter than Novo Nordisk's, the latter had a head start in the obesity drug race and is well ahead.

Novo Nordisk's Ozempic made $30 billion this past quarter, compared to $3.1 billion from Eli Lilly's Mounjaro. Ozempic makes up almost half of the market share for that category of weight loss drugs, according to Novo Nordisk.

Hyunsoo Rim

appy birthday

4/1/26

Apple is turning 50 today and it doesn’t look a thing like its younger self

From Macs to iPods, iPhones, and now services, here’s how Apple’s business has looked every 10 years.

The entrance of Allbirds seen from Hayes St. in San Francisco, Calif.

Allbirds, the once buzzy multibillion-dollar sneaker startup, is selling up for $39 million

That’s less than 1% of its peak market cap about four years ago.

Tom Jones3/31/26

Max Knoblauch3/30/26

JetBlue is raising its bag fees as fuel costs squeeze airlines

JetBlue will reportedly hike its bag fees, as the cost of jet fuel continues to climb amid the war in Iran. It’s the latest example of carriers finding ways to push rising costs onto travelers.

Last week, United Airlines CEO Scott Kirby said that if fuel prices remain elevated, fares would need to rise another 20% for his airline to break even this year.

As CNBC reported, when one airline raises fees, others tend to follow.

Earlier this month, JetBlue hiked its first-quarter outlook for operating revenue per seat mile to between 5% and 7%, saying that strong Q1 demand helped “partially offset additional expenses realized from operational disruptions and rising fuel costs.” Now, the carrier appears to be making moves to further boost revenue to offset those costs.

Earlier on Monday, JetBlue rival Alaska Air lowered its Q1 profit forecast. The refining margins for the carrier’s cheapest fuel option — sourced from Singapore and representing about 20% of Alaska’s overall supply — have spiked 400% since February.

JetBlue did not immediately respond to a request for comment.